What is the amino acid sequence for Faricimab?
The amino acid sequence for faricimab is not publicly available due to patent protections. Faricimab is a bispecific antibody designed to target angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A) [1].
What patents protect Faricimab?
Faricimab is protected by several patents that cover its composition, manufacturing, and methods of use. These patents are held by Genentech, a member of the Roche Group [1]. Specific patent numbers and their expiration dates are not readily disclosed in public summaries.
Why is the amino acid sequence kept private?
Amino acid sequences are proprietary information and are typically protected by patents to prevent competitors from replicating the drug. This is standard practice for biologic therapeutics, particularly monoclonal antibodies like faricimab, to maintain market exclusivity for the innovator company [1].
How does Faricimab work?
Faricimab is designed to inhibit two key pathways involved in neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) [1]. By neutralizing Ang-2 and VEGF-A, it aims to reduce blood vessel leakage and the formation of new, abnormal blood vessels in the eye, thereby preserving vision [1].
What is the difference between Faricimab and other eye injections?
Other treatments for AMD and DME, such as ranibizumab and aflibercept, primarily target VEGF-A [2]. Faricimab's bispecific nature, targeting both Ang-2 and VEGF-A, offers a dual mechanism of action that may provide sustained efficacy and potentially longer treatment intervals compared to single-target therapies [1][2].
When is Faricimab expected to face competition?
The competitive landscape for faricimab will be influenced by patent expirations and the potential development of biosimilars. However, given the complexity of biologic drugs and the patent protection in place, significant competition from biosimilar versions is not expected until well after the primary patent protection periods have concluded [1].
What are the clinical trial results for Faricimab?
Clinical trials have demonstrated that faricimab provides significant efficacy in treating neovascular AMD and DME. Studies have shown that patients treated with faricimab maintained vision and experienced reductions in retinal fluid, with some patients able to receive extended dosing intervals of up to every four months [1].
What are the commercial aspects of Faricimab?
Faricimab is marketed by Genentech and Roche. Its development represents a significant advancement in the treatment of retinal diseases, offering a new therapeutic option with a differentiated mechanism and potential for extended dosing convenience [1].
---
Sources
1. https://www.gene.com/media/press-releases/15043/genentech-announces-us-fda-approval-of-vat
2. https://www.nejm.org/doi/full/10.1056/NEJMoa2201497